Search Results - "Manion, Douglas J"

DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants by SCHINAZI, Raymond F, MELLORS, John, WU, Jing-Tao, HANGCHUN ZHANG, HAMMOND, Jennifer, BACHELER, Lee, MANION, Douglas J, OTTO, Michael J, STUYVER, Lieven, TRAINOR, George, LIOTTA, Dennis C, ERICKSON-VIITANEN, Susan, BAZMI, Holly, DIAMOND, Sharon, GARBER, Sena, GALLAGHER, Karen, GELEZIUNAS, Romas, KLABE, Ron, PIERCE, Michael, RAYNER, Marlene

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults by Staszewski, Schlomo, Morales-Ramirez, Javier, Tashima, Karen T, Rachlis, Anita, Skiest, Daniel, Stanford, James, Stryker, Richard, Johnson, Philip, Labriola, Dominic F, Farina, Dianne, Manion, Douglas J, Ruiz, Nancy M

“…The advent of new antiretroviral agents, most notably protease inhibitors, has generated new hope in the fight against human immunodeficiency virus type 1…”
Get full text

Therapy with Efavirenz plus Indinavir in Patients with Extensive Prior Nucleoside Reverse-Transcriptase Inhibitor Experience: A Randomized, Double-Blind, Placebo-Controlled Trial by Haas, David W., Fessel, W. Jeffrey, Delapenha, Robert A., Kessler, Harold, Seekins, Daniel, Kaplan, Mark, Ruiz, Nancy M., Ploughman, Lynn M., Labriola, Dominic F., Manion, Douglas J.

“…A randomized, double-blind, placebo-controlled trial compared efavirenz (600 mg every 24 h) plus indinavir (1000 mg every 8 h) with placebo (every 24 h) plus…”
Get full text

Antagonism between Human Immunodeficiency Virus Type 1 Protease Inhibitors Indinavir and Saquinavir In Vitro by Merrill, Debra P., Manion, Douglas J., Chou, Ting-Chao, Hirsch, Martin S.

“…Human immunodeficiency virus type 1 (HIV-1) protease inhibitors are a promising class of antiretroviral agents that compromise enzymatic function through…”
Get full text

Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity by Falloon, Judith, Piscitelli, Stephen, Vogel, Susan, Sadler, Brian, Mitsuya, Hiroaki, Kavlick, Mark F., Yoshimura, Kazuhisa, Rogers, Michael, LaFon, Steven, Manion, Douglas J., Lane, H. Clifford, Masur, Henry

“…Patients with plasma viral RNA >50,000 copies/mL, despite a protease-inhibitor regimen, received abacavir, amprenavir, and efavirenz to assess…”
Get full text

Combination chemotherapy for human immunodeficiency virus-1 by Manion, D J, Hirsch, M S

“…Combination therapy approaches are becoming the mainstay of treatment for a variety of neoplastic and infectious diseases, including human immunodeficiency…”
Get more information

Efavirenz in HIV Infection by Casado, J L, Moreno, S

“…To the Editor: Staszewski et al. (Dec. 16 issue) 1 report that “the combination of efavirenz, zidovudine, and lamivudine has greater antiviral activity . . …”
Get full text

Susceptibility of human cytomegalovirus to two-drug combinations in vitro by Manion, D J, Vibhagool, A, Chou, T C, Kaplan, J, Caliendo, A, Hirsch, M S

“…Human cytomegalovirus (HCMV) is a major cause of morbidity and mortality for immunocompromised hosts. We sought to determine the in vitro susceptibility of…”
Get more information